Rubal Sharma, MD
Hematology & Oncology · Erie, PANPI 1689163602
Payments from drug & device makers
Across 60 payments — averaging $24.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Geron Corporation$135
- Novartis$133
- Ipsen Biopharmaceuticals, Inc$126
- ADC Therapeutics America, Inc.$125
- Pfizer$81
- Incyte Corporation$76
- plus $798 from 26 others
What the payments were for
- Food & beverage$1,31189%
- Education$16411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Geron Corporation | 3 | $135 |
| Novartis | 6 | $133 |
| Ipsen Biopharmaceuticals, Inc | 3 | $126 |
| ADC Therapeutics America, Inc. | 1 | $125 |
| Pfizer | 4 | $81 |
| Incyte Corporation | 5 | $76 |
| Merck | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Johnson & Johnson(2 entities) | 3 | $57 |
| Sumitomo Pharma America, Inc. | 1 | $54 |
| AbbVie | 2 | $49 |
| GSK | 2 | $40 |
| Exelixis Inc. | 2 | $39 |
| Pharmaessentia USA Corporation | 2 | $37 |
| Medtronic | 1 | $29 |
| AstraZeneca | 1 | $26 |
| Tempus AI, Inc | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Novocure Inc. | 1 | $21 |
| Gilead | 1 | $19 |
| Myriad Genetic Laboratories, Inc. | 1 | $19 |
| Beone Medicines USA, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Legend Biotech USA Inc. | 1 | $16 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| EMD Serono, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,475 in reported general payments places this provider in the 35th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 14 | $284 |
| Prochlorperazine Maleate | 17 | $215 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Erie
- Diwakar DavarPittsburgh$21.6M
- Jason LukePittsburgh$15M
- Stephen BagleyPhiladelphia$13.1M
- Leonard ApplemanPittsburgh$12.8M
- Jing Zhou HouPittsburgh$11.9M
- Taofeek OwonikokoPittsburgh$9.7M
- Stephen SchusterPhiladelphia$9.5M
- Pooja GhataliaPhiladelphia$8.3M
- Corey LangerPhiladelphia$7.7M
- Alfred GarfallPhiladelphia$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.